1. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome
- Author
-
Hector I. Michelena, Juan A. Crestanello, Prabin Thapa, Mikhail A. Dziadzko, Giovanni Benfari, Joseph F. Maalouf, Jose R. Medina-Inojosa, Volha Dziadzko, and Maurice Enriquez-Sarano
- Subjects
Male ,medicine.medical_specialty ,Diastole ,030204 cardiovascular system & hematology ,Doppler echocardiography ,Cause ,Mechanism ,Mitral regurgitation ,Mortality ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Clinical Research ,Internal medicine ,Medicine ,Functional mr ,Humans ,030212 general & internal medicine ,Aged ,Aged, 80 and over ,Ejection fraction ,medicine.diagnostic_test ,business.industry ,Mitral Valve Insufficiency ,Middle Aged ,medicine.disease ,Treatment Outcome ,Editorial ,Heart failure ,Relative risk ,Etiology ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims To define the hitherto unknown aetiology/mechanism distributions of mitral regurgitation (MR) in the community and the linked clinical characteristics/outcomes. Methods and results We identified all isolated, moderate/severe MR diagnosed in our community (Olmsted County, MN, USA) between 2000 and 2010 and classified MR aetiology/mechanisms. Eligible patients (n = 727) were 73 ± 18 years, 51% females, with ejection fraction (EF) 49 ± 17%. MR was functional (FMR) in 65%, organic (OMR) in 32% and 2% mixed. Functional MR was linked to left ventricular remodelling (FMR-v) 38% and isolated atrial dilatation (FMR-a) 27%. At diagnosis FMR-v vs. FMR-a, vs. OMR displayed profound differences (all P Conclusion Moderate/severe isolated MR in the community displays considerable aetiology/mechanism heterogeneity. Functional MR dominates, mostly FMR-v but FMR-a is frequent and degenerative MR dominates OMR. Outcomes are mediocre with excess-mortality particularly with FMR-v but FMR-a, despite normal EF incurs notable excess-mortality and frequent heart failure. Pervasive undertreatment warrants clinical trials of therapies tailored to specific MR cause/mechanisms.
- Published
- 2018